Howard A. Fine
Neuro-Oncology Branch
National Cancer Institute/National Institute of Neurological Disorders and Stroke
National Institutes of Health
10 Center Dr
Name/email consistency: high
- Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. Edwards, L.A., Woolard, K., Son, M.J., Li, A., Lee, J., Ene, C., Mantey, S.A., Maric, D., Song, H., Belova, G., Jensen, R.T., Zhang, W., Fine, H.A. J. Natl. Cancer Inst. (2011)
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Iwamoto, F.M., Lamborn, K.R., Kuhn, J.G., Wen, P.Y., Alfred Yung, W.K., Gilbert, M.R., Chang, S.M., Lieberman, F.S., Prados, M.D., Fine, H.A. Neuro-oncology (2011)
- Glioma stem cells: not all created equal. Fine, H.A. Cancer. Cell (2009)
- A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Fine, H.A., Kim, L., Albert, P.S., Duic, J.P., Ma, H., Zhang, W., Tohnya, T., Figg, W.D., Royce, C. Clin. Cancer Res. (2007)
- Promising new therapies for malignant gliomas. Fine, H.A. Cancer. J (2007)
- Radiotherapy plus adjuvant temozolomide for the treatment of glioblastoma--a paradigm shift. Fine, H.A. Nature Clinical Practice. Oncology (2005)
- Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. Fine, H.A., Wen, P.Y., Maher, E.A., Viscosi, E., Batchelor, T., Lakhani, N., Figg, W.D., Purow, B.W., Borkowf, C.B. J. Clin. Oncol. (2003)